NCT02624999View on ClinicalTrials.gov

Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

May 31, 2017

Conditions
Squamous Cell Carcinoma Head and Neck
Interventions
BIOLOGICAL

AlloVax™

AlloVax™ combines an anti-tumor effect of mini-transplant procedures with patient specific tumor antigens

DRUG

Cisplatin

Subjects in the chemotherapy arm will receive up to 6 cycles of cisplatin on day 0 of the 3-week cycle at dose of 80-100 mg/m2 IV and 1000 mg/m2 IV 5FU on days 1-4 of the cycle

Trial Locations (1)

10400

National Cancer Institute of Thailand, Bangkok

Sponsors
All Listed Sponsors
lead

Mirror Biologics, Inc.

INDUSTRY

NCT02624999 - Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck | Biotech Hunter | Biotech Hunter